Fundz Deep Dive
Everything you need to win Teva — in one platform.
Who to reach, what to say, and why now on Teva — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Teva — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Teva and Sanofi Accelerate Anti-TL1A Phase 2b Program for Inflammatory Bowel Disease
Jul 25, 2024•almost 2 years ago
Contract Type
partnership
Tel AvivManufacturingBiotechnologyHealth CarePharmaceuticalDescription
Teva and Sanofi have announced an accelerated timeline for the anti-TL1A program, including the completion of patient enrollment in the RELIEVE UCCD Phase 2b trial and the update to the timing for topline and detailed results. They are collaborating to co-develop and co-commercialize duvakitug for moderate-to-severe UC and CD patients.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months